ZA200401976B - Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline. - Google Patents

Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline. Download PDF

Info

Publication number
ZA200401976B
ZA200401976B ZA200401976A ZA200401976A ZA200401976B ZA 200401976 B ZA200401976 B ZA 200401976B ZA 200401976 A ZA200401976 A ZA 200401976A ZA 200401976 A ZA200401976 A ZA 200401976A ZA 200401976 B ZA200401976 B ZA 200401976B
Authority
ZA
South Africa
Prior art keywords
formulation
dimethoxy
amino
pharmaceutically acceptable
methanesulfonamido
Prior art date
Application number
ZA200401976A
Other languages
English (en)
Inventor
John Douglas Davis
Michael John Humphrey
Ross James Macrae
Janet Sarah Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA200401976B publication Critical patent/ZA200401976B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200401976A 2001-10-11 2004-03-11 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline. ZA200401976B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0124455.7A GB0124455D0 (en) 2001-10-11 2001-10-11 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ZA200401976B true ZA200401976B (en) 2004-07-12

Family

ID=9923660

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200401976A ZA200401976B (en) 2001-10-11 2004-03-11 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline.

Country Status (33)

Country Link
EP (1) EP1434570B8 (fr)
JP (1) JP4131471B2 (fr)
KR (1) KR20050032510A (fr)
CN (1) CN1568180A (fr)
AP (1) AP2004003001A0 (fr)
AR (1) AR036782A1 (fr)
AT (1) ATE303135T1 (fr)
BR (1) BR0213196A (fr)
CA (1) CA2461168A1 (fr)
CO (1) CO5560534A2 (fr)
DE (1) DE60205925T2 (fr)
DK (1) DK1434570T3 (fr)
DO (1) DOP2002000464A (fr)
EA (1) EA006168B1 (fr)
ES (1) ES2246017T3 (fr)
GB (1) GB0124455D0 (fr)
GT (1) GT200200184A (fr)
HR (1) HRP20040261A2 (fr)
HU (1) HUP0600064A3 (fr)
IL (1) IL160969A0 (fr)
IS (1) IS7179A (fr)
MA (1) MA27075A1 (fr)
MX (1) MXPA04003293A (fr)
NO (1) NO20041520L (fr)
OA (1) OA12709A (fr)
PA (1) PA8556001A1 (fr)
PE (1) PE20030551A1 (fr)
PL (1) PL369666A1 (fr)
PY (1) PY0223360A (fr)
SV (1) SV2004001279A (fr)
UY (1) UY27477A1 (fr)
WO (1) WO2003032956A1 (fr)
ZA (1) ZA200401976B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
KR101943592B1 (ko) 2017-08-31 2019-01-30 조현우 데이터 마이닝 기법을 이용한 전자가계부 시스템

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053120T3 (es) * 1990-07-02 1994-07-16 Bend Res Inc Perlas microporosas asimetricas para liberacion controlada.
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
IL150634A0 (en) * 2000-03-03 2003-02-12 Pfizer 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs

Also Published As

Publication number Publication date
DOP2002000464A (es) 2003-04-15
UY27477A1 (es) 2003-05-30
PE20030551A1 (es) 2003-06-26
AP2004003001A0 (en) 2004-03-31
IS7179A (is) 2004-03-11
ATE303135T1 (de) 2005-09-15
GB0124455D0 (en) 2001-12-05
CA2461168A1 (fr) 2003-04-24
JP4131471B2 (ja) 2008-08-13
GT200200184A (es) 2003-05-23
ES2246017T3 (es) 2006-02-01
MXPA04003293A (es) 2004-07-23
KR20050032510A (ko) 2005-04-07
EP1434570B1 (fr) 2005-08-31
EP1434570A1 (fr) 2004-07-07
IL160969A0 (en) 2004-08-31
DE60205925T2 (de) 2006-06-08
JP2005507909A (ja) 2005-03-24
WO2003032956A1 (fr) 2003-04-24
MA27075A1 (fr) 2004-12-20
BR0213196A (pt) 2004-08-31
HUP0600064A2 (en) 2006-06-28
DE60205925D1 (de) 2005-10-06
PL369666A1 (en) 2005-05-02
HUP0600064A3 (en) 2007-02-28
EA006168B1 (ru) 2005-10-27
SV2004001279A (es) 2004-02-19
NO20041520L (no) 2004-04-05
CO5560534A2 (es) 2005-09-30
HRP20040261A2 (en) 2004-08-31
CN1568180A (zh) 2005-01-19
DK1434570T3 (da) 2005-11-07
EA200400431A1 (ru) 2004-08-26
OA12709A (en) 2006-06-26
AR036782A1 (es) 2004-10-06
EP1434570B8 (fr) 2005-10-26
PA8556001A1 (es) 2003-07-28
PY0223360A (es) 2004-04-01

Similar Documents

Publication Publication Date Title
CN100402021C (zh) 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)苯酚并能提供活性成分的延迟释放的药物
US7163696B2 (en) Pharmaceutical formulations
KR101774676B1 (ko) 히드로모르폰 및 날록손을 포함하는 제약 조성물
CZ294024B6 (cs) Farmaceutická dávkovací forma pro podávání do gastrointestinálního traktu pacienta obsahující darifenacin a způsob její výroby
JP2005516020A (ja) ゼロ次持続放出剤形およびその製造方法
JPH11505542A (ja) 毎日一回投与するための、非晶質活性成分の一定のかつ制御された放出を行う三相型医薬製剤
KR20040037026A (ko) 심장병 및 순환성 질병을 치료하고 예방하기 위한 하루1회 요법용 제어방출형 경구 약제학적 조성물
US20080003281A1 (en) Modified Release Tablet Formulations for Proton Pump Inhibitors
JP2003510346A (ja) 新規医薬組成物
KR102300335B1 (ko) 아프레피탄트의 경구용 조성물
WO2012101653A2 (fr) Compositions pharmaceutiques de mémantine à libération modifiée
CN104997748B (zh) 一种治疗高血压急症的硝苯地平缓释片剂及其制备工艺
KR20080037680A (ko) 1-(4-클로로아닐리노)-4-(4-피리딜메틸)프탈라진 및 ｐｈ조절제를 포함하는 고체 제약학적 조성물
EP1434570B1 (fr) Formulations pharmaceutiques destinees a la liberation controlee de 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline
WO2006130702A2 (fr) Formulations a liberation modifiee de medicaments antihypertenseurs
CA2570153A1 (fr) Granules permettant la liberation controlee de tamsulosine
JP2022514040A (ja) 耐酸性に優れたタムスロシン塩酸塩含有医薬組成物及びその製造方法
WO2002062299A2 (fr) Forme posologique orale a liberation regulee amelioree
KR102833547B1 (ko) 독실아민 석시네이트 및 피리독신 하이드로클로라이드의 변형 방출형 다중 단위 경구 제형의 제조방법
KR20160100570A (ko) 탐수로신 염산염 함유 서방성 과립을 포함하는 경구용 약제학적 제제
AU2002341260A1 (en) Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline
KR102512866B1 (ko) 아프레피탄트의 용해도가 증가된 경구용 조성물
JP2004339072A (ja) 優れた安定性を有するプラバスタチンナトリウム固形製剤
KR20170073580A (ko) 탐수로신 염산염 함유 서방성 과립을 포함하는 경구용 약제학적 제제
CN121793951A (zh) 具有提高的稳定性的包含奥美拉唑的包衣片剂组合物及其制备方法